Back

Grp78 alleviates sodium iodate-induced retinal cell injury in vivo and in vitro

liu, h.; jiang, s.; guo, y.; li, h.; yi, n.; hua liu,yongpeng guo,ning yi,hongdan li,

2021-03-22 molecular biology
10.1101/2021.03.22.436404 bioRxiv
Show abstract

ObjectiveGlucose-regulated protein 78 (Grp78) has been regarded as a main member of the endoplasmic reticulum proteins, Grp78 could protect cells from apoptosis under stress conditions. However, whether Grp78 could protect retinal pigment epithelium (RPE) cells from oxidative injury and then protect retinas from morphological changes and functional abnormalities remain undetermined. Here, we try to explore the effect of Grp78 on retinal cell injury induced by sodium iodate in vivo and in vitro. MethodsTo investigate whether Grp78 has a protective effect on RPE injury in vitro, human retinal pigment epithelium (ARPE-19) cells were treated with sodium iodate. The cell proliferation, morphology, apoptosis and ROS production assays were detected. In vivo, We established sodium iodate-induced retinal injury model in mice by intravenous injection of sodium iodate into tail vein. After that, we examined the morphology and function of retina in mice by fundus photography, OCT and ERG. Finally, we removed the retina of mice for histological examination. ResultsGrp78 significantly inhibited sodium iodate-induced reactive oxygen species (ROS), and decreased apoptosis of RPE in vitro. Furthermore, Grp78 significantly decreased the apoptosis of retinal cells in vivo, resulting in the inhibition of morphological changes of retina, and improving the function of retina. The underlying mechanisms included inhibited caspase3 and Nos, and increased expression of Bcl2, thereby protecting RPE from SI-induced ROS and apoptosis. ConclusionGrp78 could reduce the injury of retinal cells induced by sodium iodate in vitro and in vivo. These findings suggested Grp78 may become a new therapeutic target for retinal injury in clinical practice.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Annals of Translational Medicine
17 papers in training set
Top 0.1%
19.3%
2
PLOS ONE
4510 papers in training set
Top 11%
15.2%
3
Frontiers in Medicine
113 papers in training set
Top 0.2%
10.5%
4
Scientific Reports
3102 papers in training set
Top 33%
3.7%
5
Biomolecules
95 papers in training set
Top 0.1%
2.7%
50% of probability mass above
6
Acta Biochimica et Biophysica Sinica
19 papers in training set
Top 0.2%
2.0%
7
Frontiers in Aging Neuroscience
67 papers in training set
Top 2%
1.8%
8
Investigative Opthalmology & Visual Science
37 papers in training set
Top 0.4%
1.8%
9
ACS Omega
90 papers in training set
Top 1%
1.8%
10
Cell Proliferation
12 papers in training set
Top 0.1%
1.5%
11
Gene Reports
13 papers in training set
Top 0.3%
1.5%
12
International Journal of Molecular Sciences
453 papers in training set
Top 9%
1.4%
13
BMC Cardiovascular Disorders
14 papers in training set
Top 1%
1.3%
14
Genes
126 papers in training set
Top 2%
1.0%
15
Cell Cycle
14 papers in training set
Top 0.3%
1.0%
16
BMJ Open Diabetes Research & Care
15 papers in training set
Top 0.8%
1.0%
17
Frontiers in Neurology
91 papers in training set
Top 4%
0.9%
18
Frontiers in Pharmacology
100 papers in training set
Top 4%
0.9%
19
Journal of Translational Medicine
46 papers in training set
Top 2%
0.9%
20
Bioengineering
24 papers in training set
Top 0.9%
0.9%
21
Medical Research Archives
11 papers in training set
Top 0.5%
0.8%
22
ACS Chemical Neuroscience
60 papers in training set
Top 2%
0.8%
23
Aging
69 papers in training set
Top 2%
0.8%
24
PeerJ
261 papers in training set
Top 13%
0.8%
25
Clinical and Translational Medicine
30 papers in training set
Top 0.8%
0.8%
26
Experimental Eye Research
30 papers in training set
Top 0.5%
0.8%
27
Investigative Ophthalmology & Visual Science
22 papers in training set
Top 0.3%
0.8%
28
FASEB BioAdvances
15 papers in training set
Top 0.3%
0.7%
29
Antioxidants
25 papers in training set
Top 0.6%
0.7%
30
BMC Medical Genomics
36 papers in training set
Top 2%
0.5%